首页> 外文期刊>American Journal of Cancer Prevention >The Survival of Extra nodal Non-Hodgkin’s Lymphoma Patients in the West of Iran
【24h】

The Survival of Extra nodal Non-Hodgkin’s Lymphoma Patients in the West of Iran

机译:伊朗西部非淋巴结非霍奇金淋巴瘤患者的生存

获取原文
           

摘要

Background: Extra nodal Non-Hodgkin’s Lymphoma (NHL) is a heterogeneous disease in regard to geographical, ethnic, anatomic, etiological, and morphological diversities. The aim of study is evaluation of survival in extra nodal NHL patients for the first time in western Iran. Patients and Methods: Between of 2002 to 2014, fifty patients with extra nodal NHL referred to Our Clinic. We checked age, sex, histopathology reports, anatomic sites and survival for them. One representative Material of patients with diffuse large B-cell lymphoma (DLBL), Malt lymphoma, FL, SLL, anaplastic lymphoma and Burkitt’s lymphomas was re-classified after revision. The overall survival (OS) was plotted by GraphPad Prism 5 software. Results: The median age at diagnosis for the patients was 50 years (range, 13-77 years) that 26 patients (52%) had age≤ 50 years. Twenty-seven patients (54%) were male. Involvement anatomic sites were GIT, bone, abdominal, testis, skin, CNS, spleen, maxilla and adrenal gland for 19 patients(38%), 15(30%), 5(10%), 4(8%), 2(4%), 2(4%), 1(2%), 1(2%) and 1(2%), respectively. The 3-year, 5-year and 10-year survival rates are 70%, 62.2% and 60.8%, respectively. Conclusion: The OS in this study is higher than other studies and the median age is lower. Also, GIT is the most common site of involvement in extra nodal lymphomas in Middle East.
机译:背景:淋巴结外非霍奇金淋巴瘤(NHL)是一种地理,种族,解剖,病因和形态多样性方面的异质性疾病。研究的目的是首次评估伊朗西部非结节性NHL患者的生存率。患者与方法:在2002年至2014年之间,有50例额外的结节性NHL患者转诊至我们的诊所。我们检查了他们的年龄,性别,组织病理学报告,解剖部位和生存率。修订后,对弥散性大B细胞淋巴瘤(DLBL),Malt淋巴瘤,FL,SLL,间变性淋巴瘤和Burkitt淋巴瘤的一种代表性材料进行了重新分类。通过GraphPad Prism 5软件绘制总生存期(OS)。结果:患者的诊断中位年龄为50岁(13-77岁),其中26位患者(52%)的年龄≤50岁。二十七名患者(54%)是男性。涉及的解剖部位为GIT,骨,腹,睾丸,皮肤,中枢神经系统,脾,上颌和肾上腺19例(38%),15(30%),5(10%),4(8%),2( 4%),2(4%),1(2%),1(2%)和1(2%)。 3年,5年和10年生存率分别为70%,62.2%和60.8%。结论:本研究的OS高于其他研究,中位年龄较低。此外,GIT是中东地区淋巴结外淋巴瘤最常见的部位。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号